OCULAR THERAPEUTIX, INC Earnings Per Share (Basic)
OCULAR THERAPEUTIX, INC (OCUL) reported Earnings Per Share (Basic) of -$0.35 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC earnings per share, basic for the quarter ending 2026-06-30 was -$0.35.
- OCULAR THERAPEUTIX, INC earnings per share, basic for the quarter ending 2026-03-31 was -$0.40.
- OCULAR THERAPEUTIX, INC earnings per share, basic for the quarter ending 2025-09-30 was -$0.38.
- OCULAR THERAPEUTIX, INC earnings per share, basic for the quarter ending 2025-06-30 was -$0.39.
- OCULAR THERAPEUTIX, INC earnings per share, basic for fiscal 2025 was -$1.42.
- OCULAR THERAPEUTIX, INC earnings per share, basic for fiscal 2024 was -$1.22.
- OCULAR THERAPEUTIX, INC earnings per share, basic for fiscal 2023 was -$1.01.
- OCULAR THERAPEUTIX, INC earnings per share, basic for fiscal 2022 was -$0.92.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.35 10-Q · filed 2026-08-03 | -$0.75 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | -$0.40 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$1.42 10-K · filed 2026-02-05 | |||
| 2025-09-30 | -$0.38 10-Q · filed 2025-11-04 | -$1.15 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | -$0.39 10-Q · filed 2026-08-03 | -$0.77 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | -$0.38 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$1.22 10-K · filed 2026-02-05 | |||
| 2024-09-30 | -$0.22 10-Q · filed 2025-11-04 | -$0.94 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | -$0.26 10-Q · filed 2025-08-05 | -$0.73 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | -$0.49 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-02-05 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-02-05 | -$1.01 10-K · filed 2026-02-05 | |
| 2023-09-30 | -$0.01 10-Q · filed 2024-11-14 | -$0.66 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$0.26 10-Q · filed 2024-08-07 | -$0.66 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$0.39 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$0.52 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$0.76 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$0.92 10-K · filed 2025-03-03 |
| 2022-09-30 | -$0.31 10-Q · filed 2023-11-07 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.72 10-Q · filed 2023-11-07 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-03-11 |
| 2022-06-30 | -$0.24 10-Q · filed 2023-08-07 | -$0.41 10-Q · filed 2023-08-07 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.42 derived: net income ÷ weighted average shares · filed 2024-03-11 |
| 2022-03-31 | -$0.16 10-Q · filed 2023-05-08 | -$0.21 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.18 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.29 derived: net income ÷ weighted average shares · filed 2024-03-11 |
| 2021-12-31 | -$0.05 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.02 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.13 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$0.09 10-K · filed 2024-03-11 |
| 2021-09-30 | $0.03 10-Q · filed 2022-11-07 | -$0.08 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$0.04 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$0.11 10-Q · filed 2022-08-08 | -$0.07 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.04 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$2.56 10-K · filed 2023-03-06 | |||
| 2020-09-30 | -$0.19 10-Q · filed 2021-11-08 | -$1.22 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$0.64 10-Q · filed 2021-08-09 | -$1.06 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$0.41 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$0.53 10-K · filed 2020-03-12 | -$1.91 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$0.40 10-Q · filed 2020-11-05 | -$1.37 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$0.57 10-K · filed 2020-03-12 | |||
| 2019-03-31 | -$0.41 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | -$0.42 10-K · filed 2020-03-12 | |||
| 2018-09-30 | -$0.38 10-K · filed 2020-03-12 | -$1.15 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$0.37 10-K · filed 2020-03-12 | |||
| 2018-03-31 | -$0.40 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |